OP0062 EULAR POINTS TO CONSIDER FOR THE DEFINITION OF CLINICAL AND IMAGING FEATURES SUSPICIOUS FOR PROGRESSION TO PSORIATIC ARTHRITIS

Le résumé fourni par la source

Background The transition from psoriasis (PsO) to PsA is of considerable interest for potential prevention and interception of PsA[1]. Objectives To formulate EULAR points to consider (PtC) for the development of data-driven guidance and consensus for clinical trials and clinical practice in the field of prevention/interception of PsA. Methods A multidisciplinary EULAR task force of 30 European members was established and the EULAR standardized operating procedures were followed. Results Nomenclature was proposed for 3 stages towards PsA development: i) PsO patients at higher risk of PsA (i.e., nail disease, obesity, severe PsO); ii) subclinical PsA (those at more imminent risk of PsA for arthralgia and imaging abnormalities) and iii) clinical PsA that most typically manifests as synovitis (Figure 1). For the purpose of prevention, our SLR showed that the vast majority of new PsA presented with synovitis. Thus, the presence of synovitis in PsO could be used as an outcome for prevention trials. Five overarching principles (OAPs) addressed the nature of PsA at its onset and underline the importance of collaboration between rheumatologists and dermatologists (Table 1).The 10 PtC highlight arthralgia plus imaging abnormalities as key elements of subclinical PsA that can be used as potential short-term predictors of PsA development and useful criteria to design trials for PsA interception (Table 1). Conclusion These PtC are helpful to define the features of PsO patients suspicious for progression to PsA. This information may ultimately facilitate identification of those who could benefit from a therapeutic intervention to attenuate, delay, or prevent PsA development. Reference [1]Nat Rev Rheumatol. 2021 Apr;17(4):238-243 Acknowledgements: NIL. Disclosure of Interests Alen Zabotti Speakers bureau: AbbVie, Novartis, Janssen, Lilly, UCB, Amgen, Paid instructor for: AbbVie, Novartis, UCB, Gabriele De Marco Speakers bureau: Novartis, Janssen, Laure Gossec Consultant of: AbbVie, Amgen, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB, Grant/research support from: Sandoz, UCB, Xenofon Baraliakos Speakers bureau: Abbvie, BMS, MSD, Sandoz, Novartis, Pfizer, Galapagos, UCB, Lilly, Paid instructor for: Abbvie, BMS, MSD, Sandoz, Novartis, Pfizer, Galapagos, UCB, Lilly, Consultant of: Abbvie, BMS, MSD, Sandoz, Novartis, Pfizer, Galapagos, UCB, Lilly, Grant/research support from: Abbvie, MSD, Novartis, Daniel Aletaha: None declared, Annamaria Iagnocco Speakers bureau: Abbvie, MSD, Alfasigma, Celltrion, BMS, Celgene, Eli-Lilly, Sanofi Genzyme, Pfizer, Galapagos, Gilead, Novartis, SOBI, Janssen, Grant/research support from: Pfizer, Abbvie, Paolo Gisondi: None declared, Peter Balint Speakers bureau: Abbvie, Janssen, Lilly, Novartis, Heidi Bertheussen: None declared, Wolf-Henning Boehncke Speakers bureau: Abbvie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB, Consultant of: Abbvie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB, Nemanja Damjanov: None declared, Maarten de Wit: None declared, Enzo Errichetti Consultant of: AbbVie, Janssen, Novartis, Amgen, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB Pharma., Consultant of: AbbVie, Biogen, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB Pharma., Grant/research support from: Janssen, Novartis and UCB, Mikhail Protopopov: None declared, Luis Puig Speakers bureau: Janssen, Lilly, Novartis, UCB, Consultant of: Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, UCB, Grant/research support from: Abbvie, Almirall, Amgen, Boehringer Ingelheim, Leo-Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB, Rubén Queiró Silva: None declared, Piero Ruscitti: None declared, Laura Savage Speakers bureau: AbbVie, Almirall, Amgen, Aspire Pharma, Biogen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celgene, Celltrion, Fresensius Kabi, Galderma, Janssen, Leo, Lilly, Novartis, Pfizer, MSD, Sanofi, Takeda, UCB, Consultant of: AbbVie, Boehringer-Ingelheim, Bristol-Myers-Squibb, Fresensius Kabi, Janssen, Lilly, Novartis, UCB, Grant/research support from: Janssen, Pfizer, Georg Schett: None declared, Stefan Siebert Speakers bureau: AbbVie, GSK, Janssen, UCB, Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, UCB, Grant/research support from: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Janssen and UCB, Tanja Stamm Speakers bureau: AbbVie, Roche, Sanofi, Takeda and Novartis, Grant/research support from: AbbVie and Roche, Paul Studenic Speakers bureau: Astra Zeneca, Ilaria Tinazzi Speakers bureau: Janssen, Pfizer, Filip van den Bosch: None declared, Annette van der Helm – van Mil: None declared, Abdulla Watad: None declared, Josef S. Smolen: None declared, Dennis McGonagle Speakers bureau: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB, Consultant of: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB, Grant/research support from: AbbVie, Celgene, Janssen, Merck, Novartis, Pfize.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.